Most recently, a phase 1 trial in gliomas has been launched to determine the safety and tolerability of IDH1 R132H peptide vaccine, PD-L1 checkpoint inhibitor (Avelumab) or their combination (ClinicalTrials.gov NCT03893903). Here, IDH1 is linked to glioma.